Among genetically modified NK cells, glypican-3 (GPC3) specific CAR-NK-92 cells were reported to have high antitumor activity against HCC xenografts expressing both low and high levels of GPC3. This evidence concerns the gene GPC3 and hepatocellular carcinoma.